BackNgm Biopharmaceuticals Overview

Ngm Biopharmaceuticals Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$21.37M
54.26% YoY

As of Dec 31, 2023

Annual R&D Expenses (TTM)

$117.52M
35.09% YoY

Trailing 12 months ending Dec 31, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Ngm Biopharmaceuticals (NGM) FAQ

Stockcircle tracks research & development for Ngm Biopharmaceuticals (NGM), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Ngm Biopharmaceuticals's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main NGM overview so you can move from this figure to the surrounding analysis quickly.